About this trial
Endocrine therapy is the mainstay of adjuvant therapy in premenopausal women with hormone receptive-positive (HR+) breast cancer as it has been demonstrated that it reduces long-term recurrences and increases survivial. However, this therapy, which suppresses estrogen production and estrogen-induced effects, is associated with the development of joint pain which can significantly reduce quality of life and lead to treatment discontinuation.
The main question the study aims o answer is:
Can balneotherapy (BT) alleviate muscle-skeletal pain (primary objective) derived from endocrine therapy and improve quality of life (secondary objective) in young women with HR+ breast cancer?
Eligibility criteria
Qualifiers
None
Disqualifiers
Chronic musculoskeletal conditions predating the initiation of endocrine therapy and/or unrelated to effects derived from the endocrine therapy (i.e. fibromyalgia)
Anxiety-depression syndrome predating the initiation of endocrine therapy that is treated with drugs.
Fear of water
Fecal and/or urinary incontinence
Trial design
Treatments tested in this trial
- Balneotherapy
Treatment groups
Sponsors and collaborators
Parc de Salut Mar
Lead sponsor
Caldes de Montbui's City Council
Collaborator
European Regional Development Fund
Collaborator
Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES)
Collaborator